ÍþÁ®Ï£¶û¹ÙÍøµØÖ·

ÈÈÃÅËÑË÷
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾ Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
ÐÂÎÅ×ÊѶ
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
2026-04-17
ÓÃÐж¯»ã¾ÛÂÌɫδÀ´ | ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïÊ×½ì¾ÉÎï½»Á÷¹«ÒæÔ˶¯Ô²Âú¿¢ÊÂ
4ÔÂ15ÈÕ£¬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïÊ׽조½»Á÷´ºÌ졤¾ÉÎïÐÂÉú¡±¹«ÒæÔ˶¯ÔÚ±õ½­Ó븻Ñô¶«ÖÞµÄÈý´óÔ°ÇøÍ¬²½ÆôÄ»¡£200ÓàÃûÔ±¹¤Æë¾ÛÐæÊУ¬ÒÔÎï»»ÎïÅÌ»îÏÐÖÃ×ÊÔ´£¬Èû·±£µÄÖÖ×ÓÔÚ´ºÈÕÔú¸ù£¬ÒÔÂÌÉ«Ðж¯¼ùÐÐÆóÒµ¿ÉÒ»Á¬Éú³¤ÀíÄî¡£Ò»¡¢¾ÉÎï²»ÏС­
Éó²éÏêÇé
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
042026.03
ÍþÁ®Ï£¶û¹ÙÍøµØÖ· Immutailin? PVDFתӡĤÐÂÆ·ÉÏÊÐ
ÔÚÂѰ×ÖÊÓëºËËá¼ì²âÆÊÎöÓ¦ÓÃÖУ¬NC תӡĤ£¨ÏõËáÏËÎ¬ËØÄ¤£©ÓëPVDF ×ªÓ¡Ä¤£¨¾ÛÆ«¶þ·úÒÒϩĤ£©ÊÇÁ½Ïî½¹µãµÄ¹ÌÏàÖ§³Ö½éÖÊ¡£ËüÃÇÒÀ¸½¸÷×ÔÆæÒìµÄÐÔÄÜÓÅÊÆ£¬ÆÕ±éÓ¦ÓÃÓÚ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
242026.02
¿¥ÆôгÌ£¬ÂíÁ¦È«¿ª£¡ ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï½ñÈÕ¿ª¹¤À²£¡
·Ü½øÕýÆäʱ£¬¿ª¹¤Æôг̣¡ÏÄÀúÕýÔ³õ°ËÉÏÎ磬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïдº¿ª¹¤ÒÇʽÔÚ¸÷¸öÔ°ÇøÍ¬²½¾ÙÐС£È«ÌåÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÈË´ø×ÅдºµÄÉúÆøÖØ·µ¸Úλ£¬Ñ¸ËÙ´Ó¡°¼ÙÆÚģʽ¡±Çл»ÖÁ¡°ÊÂÇéģʽ¡±£¬ÒÔ»ðÈÈ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
112026.02
2025ÍþÁ®Ï£¶û¹ÙÍøµØÖ·Äê¶È·þÎñ±¨¸æ¡ª¡ªÒÔ·þÎñÖ®¹â£¬ÕÕÁÁ¿Æ¼¼Ö®Â·
¡°ÒÔ¿Í»§ÎªÖÐÐÄ¡±ÊÇÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïµÄ·þÎñ×ÚÖ¼ÎÒÃÇÓÅ»¯Á÷³Ì¡¢Á¢Òì¼Æ»®ÓÃÐж¯Ú¹ÊÍ·þÎñ¼ÛÖµÓÃרҵÓëζÈÓ®µÃ¿Í»§ÐÅÈÎÕâÒ»ÄêÀۼƷþÎñ16,000+¼Ò¿Í»§·þÎñ×ã¼£±é²¼10+¸ö¹ú¼Ò30+¸ö¶¼»á&nb¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
112026.02
?ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸ºÑ¹¸ôÀëÆ÷ÊÖÒÕÔڸ߻îÐÔÖÊÁÏÒ©Éú²úÖеÄÓ¦ÓÃ
Ò»¡¢¹æÔò¶Ô¶¾ÐÔÒ©Æ·Éú²úµÄÏà¹Ø»®¶¨¡ñ WHO TRS-957 ANNEX 3 WHO good manufacturing practices for pharmaceutical products containing hazardous substance¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
302026.01
ÍòÂíÍØÐ ¹²Ô¾É½º£ | ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÔ²ÂúÂäÄ»£¡
1ÔÂ28ÈÕ£¬¡°ÍòÂíÍØÐ ¹²Ô¾É½º£¡±¡ª¡ªÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÊ¢´ó¾ÙÐС£ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¶­Ê³¤Ò¶´óÁÖÏÈÉú£¬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸±×ܲÃÉòÖ¾ÁÖÏÈ¡­
ÍøÕ¾µØÍ¼